Boehringer Ing. — Medicare Part D spending
Rank #4 by attributed Part D spend · 27 tracked drugs · CMS data year 2023
About $15,717,354,549 of Medicare Part D spending in 2023 is attributed to Boehringer Ing. across the 27 of its drugs tracked here, ranking it #4 among manufacturers on this site. Its biggest Part D drug is Jardiance at $8,839,935,063. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Boehringer Ing. drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/jardiance-empagliflozin/">Jardiance</a> | Empagliflozin | $8,839,935,063 | $20.32 | 1,882,768 | #3 |
| <a href="/drug/ofev-nintedanib-esylate/">Ofev</a> | Nintedanib Esylate | $1,837,061,150 | $220.84 | 20,444 | #24 |
| <a href="/drug/tradjenta-linagliptin/">Tradjenta</a> | Linagliptin | $1,293,567,778 | $18.04 | 286,808 | #36 |
| <a href="/drug/spiriva-respimat-tiotropium-bromide/">Spiriva Respimat</a> | Tiotropium Bromide | $923,556,171 | $123.39 | 333,929 | #55 |
| <a href="/drug/spiriva-handihaler-tiotropium-bromide/">Spiriva Handihaler</a> | Tiotropium Bromide | $782,927,125 | $17.73 | 236,984 | #67 |
| <a href="/drug/combivent-respimat-ipratropium-albuterol-sulfate/">Combivent Respimat</a> | Ipratropium/Albuterol Sulfate | $456,397,647 | $125.19 | 176,341 | #118 |
| <a href="/drug/stiolto-respimat-tiotropium-br-olodaterol-hcl/">Stiolto Respimat</a> | Tiotropium Br/Olodaterol HCl | $432,253,137 | $118.33 | 155,872 | #126 |
| <a href="/drug/synjardy-xr-empagliflozin-metformin-hcl/">Synjardy XR</a> | Empagliflozin/Metformin HCl | $278,415,269 | $14.67 | 58,868 | #173 |
| <a href="/drug/pradaxa-dabigatran-etexilate-mesylate/">Pradaxa</a> | Dabigatran Etexilate Mesylate | $176,220,137 | $2.44 | 144,821 | #257 |
| <a href="/drug/synjardy-empagliflozin-metformin-hcl/">Synjardy</a> | Empagliflozin/Metformin HCl | $163,646,663 | $10.25 | 35,768 | #273 |
| <a href="/drug/glyxambi-empagliflozin-linagliptin/">Glyxambi</a> | Empagliflozin/Linagliptin | $136,590,648 | $20.66 | 27,116 | #314 |
| <a href="/drug/atrovent-hfa-ipratropium-bromide/">Atrovent HFA</a> | Ipratropium Bromide | $131,864,275 | $37.36 | 68,099 | #323 |
| Jentadueto | Linagliptin/Metformin HCl | $93,638,309 | $9.06 | 20,684 | #414 |
| Trijardy XR | Empaglifloz/Linaglip/Metformin | $76,136,040 | $14.81 | 16,941 | #475 |
| Gilotrif | Afatinib Dimaleate | $51,441,559 | $387.32 | 816 | #610 |
| Jentadueto XR | Linagliptin/Metformin HCl | $29,897,203 | $13.36 | 7,327 | #792 |
| Striverdi Respimat | Olodaterol HCl | $5,086,062 | $65.22 | 3,476 | #1487 |
| Micardis | Telmisartan | $1,974,182 | $4.68 | 1,322 | #1847 |
| Spevigo | Spesolimab-Sbzo | $1,705,416 | $3,552.95 | 20 | #1903 |
| Cyltezo(Cf) Pen | Adalimumab-Adbm | $1,417,328 | $3,490.95 | 88 | #1963 |
| Aptivus | Tipranavir | $1,283,060 | $17.69 | 65 | #1999 |
| Micardis HCT | Telmisartan/Hydrochlorothiazid | $947,481 | $4.71 | 674 | #2126 |
| Mirapex ER | Pramipexole Di-HCl | $794,263 | $24.24 | 119 | #2188 |
| Cyltezo(Cf) | Adalimumab-Adbm | $275,108 | $3,438.85 | 19 | #2545 |
| Catapres-Tts 3 | Clonidine | $215,813 | $173.76 | 37 | #2608 |
| Catapres-Tts 2 | Clonidine | $74,920 | $119.87 | 28 | #2868 |
| Catapres-Tts 1 | Clonidine | $32,741 | $72.76 | 27 | #3066 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Boehringer Ing. get?
In 2023, about $15,717,354,549 of Medicare Part D spending is attributed to Boehringer Ing. across the 27 of its drugs tracked here. Its biggest is Jardiance at $8,839,935,063. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Boehringer Ing.'s top Medicare Part D drug?
Among the drugs tracked here, Boehringer Ing.'s highest Part D spending in 2023 is Jardiance at $8,839,935,063 (national rank #3 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21